 OncLive | Plenary Sunday at ASCO OncLive Bendamustine—an alkylating agent developed at that time—combined with rituximab produced superior outcomes and fewer toxicities than CHOP plus rituximab in patients with indolent and mantle cell lymphomas. Last but definitely not least was the ... |
